|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 美国临床生化科学院检验医学实践指南:睾丸、前列腺、结直肠、乳腺及卵巢癌肿瘤标志物的应用显示文摘经美国临床生化科学院(NCAB)授权,由鄢盛恺教授组织学者、专家翻译审定2009年NCAB检验医学实践指南:睾丸、前列腺、结直肠、乳腺及卵巢癌中肿瘤标志物的应用单行本(Catharine M.Sturgeon教授和Eleftherios P.Diaman-dis教授编辑)。该指南包含第1至6章共6部分内容,参加指南制订的专家阵容强大,分别从临床及检验角度对睾丸、前列腺、结直肠、乳腺及卵巢癌中肿瘤标志物的检测与临床应用方面的问题进行了详细阐述与说明,是目前国内外在肿瘤实验诊断方面的纲领性应用文件。不仅适合广大检验人员、临床医护人员学习使用,也非常适合相关仪器试剂生产厂商研发应用。本指南由刘洋、薛丽、林文涛、李江、梁红艳、顾兵、潘世扬、郑磊等翻译,姜晓峰、沈文梅、田亚平、鄢盛恺审校,最后由鄢盛恺统稿审定。本指南的翻译出版,不仅有助于我国检验人员和医护人员合理的检测和应用睾丸、前列腺、结直肠、乳腺及卵巢癌肿瘤标志物,对我国检验医学指南的编写与应用也有一定的借鉴作用。本刊特在本期刊发,以飨广大读者。 | 鄢盛恺 Ulf-Hkan Stenman Rolf Lamerz Leendert H.Looijenga Nils Brünner Michael J.Duffy Caj Haglund Mads Holten-Andersen Hans JФrgen Nielsen Francisco J.Esteva Nadia Harbeck Daniel F.Hayes Rafael Molina Daniel W.Chan Robert C.Bast Jr Ie-Ming Shih Lori J.Sokoll Gyrgy Slétormos 刘洋 梁红艳 姜晓峰 田亚平 薛丽 林文涛 顾兵 潘世扬 沈文梅 郑磊 李江 | 2012 | 临床检验杂志2012，30，2： | 32 |
| 2 | Quality of life following laparoscopic Nissen fundoplication: Assessing short-term and long-term outcomes显示文摘AIM: To investigate the quality of life following lapa-roscopic Nissen fundoplication by assessing short-term and long-term outcomes. METHODS: From 1992 to 2005, 249 patients under-went laparoscopic Nissen fundoplication. Short-term outcome data including symptom response, side effects of surgery, endoscopy, and patient's perception of over-all success were collected prospectively. Long-term out-comes were investigated retrospectively in patients witha median follow-up of 10 years by assessment of reflux symptoms, side effects of surgery, durability of antire-flux surgery, need for additional treatment, patient's perception of success, and quality of life. Antireflux sur-gery was considered a failure based on the following criteria: moderate to severe heartburn or regurgitation; moderate to severe dysphagia reported in combination with heartburn or regurgitation; regular proton pump inhibitor medication use; endoscopic evidence of erosive esophagitis Savary-Miller grade 1-4; pathological 24-h pH monitoring; or necessity to undergo an additional surgery. The main outcome measures were short-and long-term cure rates and quality of life, with patient sat-isfaction as a secondary outcome measure. RESULTS: Conversion from laparoscopy to open sur-gery was necessary in 2.4% of patients. Mortality was zero and the 30-d morbidity was 7.6% (95%CI: 4.7%-11.7%). The median postoperative hospital stay was 2 d [interquartile range (IQR) 2-3 d]. Two hundred and forty-seven patients were interviewed for short-term analysis following endoscopy. Gastro-esophageal reflux disease was cured in 98.4% (95%CI: 95.9%-99.6%) of patients three months after surgery. New-onset dysphagia was encountered postoperatively in 13 patients (6.7%); 95% reported that the outcome was better after antireflux surgery than with preopera-tive medical treatment. One hundred and thirty-nine patients with a median follow-up of 10.2 years (IQR 7.2-11.6 years) were available for a long-term evalu-ation. Cumulative long-term cure rates were 87.7% (81.0%-92.2%) at 5 years and 72.9% (64.0%-79.9%) at 10 years. Gastrointestinal symptom rating scores and RAND-36 quality of life scores of patients with treatment success were similar to those of the general population but significantly lower in those with failed antireflux surgery. Of the patients available for long-term follow-up, 83% rated their operation a success. CONCLUSION: For the long-term, our results indicate decreasing effectiveness of laparoscopic antirefluxsurgery, although most of the patients seem to have an overall quality of life similar to that of the general population. | Ilmo Kellokumpu Markku Voutilainen Caj Haglund Martti Frkkil Peter J Roberts Hannu Kautiainen | 2013 | World Journal of Gastroenterology2013，19，24： | 7 |
| 3 | Carbonic anhydrase enzymes Ⅱ, Ⅶ, Ⅸ and Ⅻ in colorectal carcinomas显示文摘AIM To investigate expression of four alpha-carbonic anhydrases(CAs) in colorectal carcinomas(CRC) and compare the results with patients' survival.METHODS Colorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against CA Ⅱ, CA Ⅶ, CA Ⅸ, and CA Ⅻ. Intensity and extent of staining were both scored from 0 to 3 in each sample. These enzyme expression levels were then correlated to patients' survival and clinicopathological parameters, which were tumor differentiation grade and stage, site of tumor, patients' age, and gender. Kaplan-Meier analysis and Cox regression hazard ratio model were used to analyze survival data. RESULTS CA Ⅱ and CA Ⅻ staining intensities correlated with patients' survival in that higher expression indicated poorer prognosis. In Cox regression analysis one unit increase in the CA Ⅱ intensity increased the hazard ratio to 1.19 fold(CI: 1.04-1.37, P = 0.009). A significant correlation was also found when comparing CA Ⅻ staining intensity with survival of CRC patients(HR = 1.18, 95%CI: 1.01-1.38, P = 0.036). The extent of CA Ⅻ immunostaining did not correlate to the patients' survival(P = 0.242, Kaplan-Meier analysis). A significant interaction between age group and extent of the CA Ⅱ staining was found. Increased extent of CA Ⅱ had a significant hazard ratio among patients 65 years and older(1.42, 95%CI: 1.16-1.73, P = 0.0006). No correlations were found between CA Ⅶ(intensity P = 0.566, extent P = 0.495, Kaplan-Meier analysis), or CA Ⅸ(intensity P = 0.879, extent P = 0.315, KaplanMeier analysis) immunostaining results and survival, or the other parameters. CONCLUSION The present findings indicate that CA Ⅱ and CA Ⅻ could be useful in predicting survival in CRC. | Pia Viikil? Antti J Kivel? Harri Mustonen Selja Koskensalo Abdul Waheed William S Sly Jaromir Pastorek Silvia Pastorekova Seppo Parkkila Caj Haglund | 2016 | World Journal of Gastroenterology2016，22，36： | 3 |
| 4 | Clinical utility of biochemical markers in colorectal cancer:European Group on Tumour Markers(EGTM)guidelines显示文摘 | Duffy M J van Dalen A Haglund C | 2003 | Eur J Cancer2003，39，6： | 1 |
| 5 | The relevance of WHO injury surveillance guidelines for evaluation: learning from the aboriginal community-centered injury surveillance system (ACCISS) and two institution-based systems 显示文摘 | Auer AM Dobmeier TM Haglund B J et M | 2011 | BMC Public Heahh2011，11，： | 1 |
| 6 | Clinical utility of biochemical markers in colorectal cancer:European Group on Tumour Markers(EGTM) guidelines显示文摘 | Duffy M J Dalen A Haglund C | 2003 | European Journal of Cancer2003，39，： | 1 |
| 7 | An in Site Gelfingsystem for Parenteral Delivery显示文摘 | Haglund B O Joshi R Himmelstein K J | 1996 | Controlled Release1996，41，： | 1 |
| 8 | Ca242 a new tumor marker for pancreatic cancer显示文摘 | Haglund C Lundin J Kuusela D | 1994 | Br J Cancer1994，70，： | 1 |
| 9 | Two-dimensional current percolation in nanocrystalline vanadium dioxide films 显示文摘 | Rozen J Lopez R Haglund R F Jr | 2006 | Applied Physics Letters2006，88，08： | 1 |
| 10 | Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract显示文摘 | Bassil A K Haglund Y Brown J | 2007 | Br J Pharmacol2007，150，1： | 1 |
| 11 | IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations 显示文摘 | Haglund S Taipalensuu J Peterson C | 2008 | Br J Clin Phar- macol2008，65，1： | 1 |
| 12 | Pulmonary enflostatin perinatally and in lung injury of the newborn infant显示文摘 | Joakim J Andersson S Haglund C | 2007 | Pediatrics2007，119，1： | 1 |
| 13 | Size effects in the structural phase transition of V02 nanoparticles studied by surface-enhanced raman scattering 显示文摘 | DONEV E U ZIEGLER J I HAGLUND R F | 2009 | J Opt A: Pure Appl Opt2009，11，12： | 1 |
| 14 | Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope 显示文摘 | Haglund K Forman J Krausslich H G | 2000 | Virology2000，268，： | 1 |
| 15 | Influence of cyclo-oxygenase inhibitors on gut immune cell distribution and apoptosis rate in experimental sepsis 显示文摘 | Osterberg J Ljungdahl M Haglund U | 2006 | Shock2006，25，2： | 1 |
| 16 | CA242 a new tumor marker for pancreatic cancer显示文摘 | Haglund C Lundin J Kuuseda D | 1994 | Br J Cancer1994，70，： | 1 |
| 17 | Comparison of a new tumor marker CA242 with CA199 CA50 and Carcinoembryonic antigen (CEA) in digestive tract diseases tract diseases显示文摘 | Kuusela P Haglund C Roberts P J | 1991 | Br J Cancer1991，63，4： | 1 |
| 18 | Fibroblast growth factors and their receptors in cancer 显示文摘 | Wesche J Haglund K Haugsten EM | 2011 | Biochem J2011，437，2： | 1 |
| 19 | CA242,a new tumor marker for pancreatic cancer:a comparison with CA19-5,CA50 and CEA显示文摘 | Haglund C Lundin J Kuusela P | 2006 | Br J Cancer2006，，70： | 1 |
| 20 | Fibroblast growthfactors and their receptors in cancer显示文摘 | WESCHE J HAGLUND K HAUGSTEN E M | 2011 | Biochem J2011，437，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员